<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190761</url>
  </required_header>
  <id_info>
    <org_study_id>40464</org_study_id>
    <nct_id>NCT01190761</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the rate and extent of absorption of Purepac, a
      subsidiary of Alpharma Inc., U.S.A., galantamine and Janssen Pharmaceutica Products, L.P.,
      U.S.A. (Reminyl),galantamine, administered as a 1 x 4 mg tablet, under fed conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, 2-period, 2-sequence, crossover design.

      Official Title: Randomized, 2-Way Crossover, Bioequivalence Study of Galantamine 4 mg Tablet
      and Reminyl Following a 4 mg Dose in Healthy Subjects Under Fed Conditions.

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Rate and Extend of Absorption
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>36 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galantamine 4 mg Tablet, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reminyl 4 mg Tablet, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galantamine 4 mg Tablet, single dose</intervention_name>
    <description>A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Galantamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reminyl 4 mg Tablet, single dose</intervention_name>
    <description>B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Galantamine hydrobromide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects enrolled in this study will be members of the community at large. The recruitment
        advertisements may use various media types (e.g. radio, newspaper, SFBC Anapharm Web site,
        SFBC Anapharm volunteers' database). Subjects must meet all of the following criteria in
        order to be included in the study:

          -  Male or female, smoker or non-smoker, 18 years of age and older

          -  Capable of consent.

          -  BMI2:19.0 and &lt;30.0 kg/rn&quot;.

        Exclusion Criteria:

        Subjects to whom any of the following applies will be excluded from the study:

        â€¢ Clinically significant illnesses within 4 weeks prior to the administration of the study
        medication.

        Clinically significant surgery within 4 weeks prior to the administration of the study
        medication.

          -  Any clinically significant abnormality found during medical screening.

          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the
             subject from participating in the study.

          -  Abnormal laboratory tests judged clinically significant.

          -  Positive testing for hepatitis B, hepatitis C, or HN at screening.

          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood
             pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or
             over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.

          -  History of significant alcohol abuse or drug abuse within one year prior to the
             screening visit.

          -  Regular use of alcohol within six months prior to the screening visit (more than
             fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL
             of 40% alcohol]).

          -  Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or
             hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the
             screening visit or positive urine drug screen at screening.

          -  History of allergic reactions to heparin, galantamine, other tertiary alkaloid
             derivatives or other related drugs.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of
             inducers: barbiturates, carbamazepine, phenytoine, glucocorticoids, omeprazole;
             examples of inhibitors: antidepressant (SSRI), cimetidine, diltiazem, macrolides,
             imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days
             prior to administration of the study medication.

          -  Use of an investigational drug or participation in an investigational study within 30
             days prior to administration of the study medication.

          -  Clinically significant history or presence of any clinically significant
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney
             disease, or other conditions known to interfere with the absorption, distribution,
             metabolism, or excretion ofthe drug.

          -  Any clinically significant history or presence of clinically significant neurological,
             endocrinal, cardiovascular, pulmonary (including asthma and COPD), hematologic,
             immunologic, psychiatric, or metabolic disease.

        Use of prescription medication (including hormone therapy) within 14 days prior to
        administration of study medication or over-the-counter products (including natural food
        supplements, vitamins, garlic as a supplement) within 7 days prior to administration of
        study medication, except for topical products without systemic absorption or hormonal
        contraceptive.

          -  Difficulty to swallow study medication.

          -  Smoking more than 25 cigarettes per day.

          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the
             Medical Sub-Investigator, could contraindicate the subject's participation in this
             study.

          -  A depot injection or an implant of any drug (other than hormonal contraceptive) within
             3 months prior to administration of study medication.

          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or
             loss of whole blood (excluding the volume of blood that will be drawn during the
             screening procedures of this study) prior to administration of the study medication as
             follows:

          -  50 mL to 300 mL of whole blood within 30 days,

          -  301 mL to 500 mL of whole blood within 45 days, or

          -  more than 500 mL of whole blood within 56 days prior to drug administration.

          -  History of &quot;sick sinus syndrome&quot; or other supraventricular cardiac conduction
             disorders,active coronary artery disease or congestive heart failure.

          -  History of unexplained syncopal episodes.

          -  Consumption of food or beverages containing grapefruit (e.g. fresh, canned, or
             frozen)within 7 days prior to administration of the study medication.

          -  History of ulcer disease.

          -  History of asthma or obstructive pulmonary disease.

          -  History of seizure disorder.

          -  Breast-feeding.

          -  Positive urine pregnancy test at screening.

          -  Female subjects of childbearing potential having unprotected sexual intercourse with
             any non-sterile male partner (i.e. male who has not been sterilized by vasectomy for
             at least 6 months) within 14 days prior to study drug administration. Acceptable
             methods of contraception:

          -  condom + spermicide;

          -  diaphragm + spermicide;

          -  intra-uterine contraceptive device (placed at least 4 weeks prior to study drug
             administration);

          -  hormonal contraceptives (starting at least 4 weeks prior to study drug
             administration).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G 1 V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://chem.sis.nlm.nih.gov/chemidplus/ProxyServlet?QV1=GALANTAMINE&amp;QO1=%3D&amp;QF1=Name&amp;objectHandle=Search&amp;actionHandle=searchChemIdLite&amp;responseHandle=JSP&amp;nextPage=jsp%2Fchemidlite%2FChemidDataview.jsp</url>
    <description>GALANTAMINE</description>
  </link>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <last_update_submitted>August 27, 2010</last_update_submitted>
  <last_update_submitted_qc>August 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Galantamine</keyword>
  <keyword>Reminyl</keyword>
  <keyword>Galantamine hydrobromide</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Galantamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

